Law360, New York (September 10, 2009) -- Abbott Laboratories said Thursday it had agreed to acquire cardiac device maker Evalve Inc. in a $410 million deal meant to expand the company’s reach in the market for minimally invasive repair of cardiac mitral valves.
The agreement includes an upfront payment of $320 million in cash, plus an additional payment upon completion of certain regulatory milestones, for a total of up to $410 million, Abbott...
